Drug Trial Radar · NCT07284420
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Dec 19, 2025
Primary completion
Mar 7, 2028
Study completion Mar 7, 2028
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive generalized myasthenia gravis. The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170 More information can be found here: https://clinicaltrials.argenx.com/adaptforward1
Conditions
- AChR-Ab Seropositive Generalized Myasthenia Gravis
- Myasthenia Gravis
- MG
- gMG
- Generalized Myasthenia Gravis
- Generalized Myasthenia Gravis (gMG)
Interventions
Efgartigimod IVBiological
Intravenous infusion of efgartigimod
Empasiprubart IVBiological
Intravenous infusion of empasiprubart
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events and serious adverse events in parts A and BTime frame: Up to 21 weeks
Locations
33 sites in 8 countries. Site status is shown where the registry gives one.
Profound Research LLC - Carlsbad
Carlsbad, California · Recruiting
Visionary Investigators Network
Miami, Florida · Recruiting
University of South Florida
Tampa, Florida · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Henry Ford Health Systems
Detroit, Michigan · Recruiting
Profound Research LLC at Las Vegas Neurology Center
Las Vegas, Nevada · Recruiting
Dent Neurologic Institute - Amherst
Amherst, New York · Recruiting
University of North Caroline at Chapel Hill-170 Manning Dr
Chapel Hill, North Carolina · Recruiting
Duke Early Phase Clinical Research Unit - PPDS
Durham, North Carolina · Recruiting
University of Cincinnati Medical Center - Goodman St
Cincinnati, Ohio · Recruiting
Ohio State Martha Morehouse Outpatient Care
Columbus, Ohio · Recruiting
Erlanger Health System
Chattanooga, Tennessee · Recruiting
National Neuromuscular Research Institute
Austin, Texas · Recruiting
University of Texas- San Antonio - Health Science Center - PPDS
San Antonio, Texas · Recruiting
UZ Leuven - PPDS
Leuven, Belgium · Recruiting
Charité - Universitätsmedizin Berlin
Berlin, Germany · Recruiting
Universitätsmedizin Göttingen
Göttingen, Germany · Recruiting
Universitätsklinikum Würzburg
Würzburg, Germany · Recruiting
Eginitio Hospital
Athens, Greece · Recruiting
AHEPA University General Hospital of Thessaloniki
Thessaloniki, Greece · Recruiting
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy · Recruiting
AORN Antonio Cardarelli
Naples, Italy · Recruiting
ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII
Bergamo, Lombardy, Italy · Recruiting
General Hanamaki Hospital - Kajomachi
Hanamaki, Japan · Recruiting
IUHW Narita Hospital
Narita, Japan · Recruiting
University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan · Recruiting
St. Marianna University Hospital
Kawasaki-shi, Kanagawa, Japan · Recruiting
National Hospital Organization Sendai Medical Center
Sendai, Miyagi, Japan · Recruiting
Warszawski Uniwersytet Medyczny
Warsaw, Poland · Recruiting
MICS Centrum Medyczne Bydgoszcz
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting
Centrum Medyczne Neurologia Slaska
Katowice, Silesian Voivodeship, Poland · Recruiting
Hospital de La Santa Creu i Sant Pau
Barcelona, Spain · Recruiting
Hospital Regional Universitario de Malaga - Hospital General
Málaga, Malaga, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.